Ensysce Biosciences, Inc. (ENSC) News
Follow Ensysce Biosciences, Inc. (ENSC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ensysce Biosciences, Inc. (ENSC) Submits CY200 Phase 2a Protocol to UK MHRA
Ensysce Biosciences submitted a Phase 2a protocol to the UK MHRA for CY200 in CRPS Type 1, a randomized, placebo-controlled proof-of-concept study planned in the UK.Material DetailsContext by AI AnalystThis is an early c
NEWS | Sep 24, 2026, 12:03 PM UTC
L
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~SAN DIEGO, CA / / September 24, 2026 / Ensysce Biosciences, Inc. NASDAQ:ENSC ("Ensysce" or the "Company"), a clini
NEWS | Sep 24, 2026, 12:02 PM UTC
L
ENSC - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
ENSC - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
NEWS | Sep 24, 2026, 12:00 PM UTC
L
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / / September 15, 2026 / Ensysce Biosciences, Inc. NASDAQ:ENSC ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an
REGULATION | Sep 15, 2026, 01:21 PM UTC
L
ENSC - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
ENSC - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
REGULATION | Sep 15, 2026, 01:15 PM UTC
L
Ensysce Biosciences to participate in upcoming conference events
Ensysce Biosciences said it will take part in upcoming conference and industry event participation.
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
ENSC - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
ENSC - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
ENSC - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
ENSC - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
EQUITY | Aug 20, 2026, 12:00 PM UTC
L
Ensysce Biosciences reports Q2 2026 financial results
Ensysce Biosciences (ENSC) reports second quarter 2026 financial results and recent business highlights, per TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:15 PM UTC
L
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 54,373.37 while the NASDAQ fell 0.24% to 26,299.39. T
EARNINGS | Aug 06, 2026, 01:43 PM UTC
H
Small Caps Surge
Several small caps see large gains
EQUITY | Aug 04, 2026, 01:13 PM UTC
H
Premarket Gainers: RAIN +101.87%
Top premarket gainers
EQUITY | Aug 04, 2026, 09:40 AM UTC
H
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Shares of Palantir Technologies Inc (NASDAQ: PLTR ) rose sharply in pre-market trading, after the company posted upbeat financial results for the second quarter and raised its FY26 sales guidance. Palantir reported secon
EARNINGS | Aug 04, 2026, 08:42 AM UTC
H
ENSC Hits High On Patent News
ENSC rises on patent news
EQUITY | Aug 03, 2026, 08:09 PM UTC
L
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Seer (NASDAQ: SEER ) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ: UPC ) stock m
EQUITY | Jul 02, 2026, 09:05 PM UTC
M
ENSC Initiates PF614-MPAR-102 Trial
Ensysce Biosciences initiates final stage of PF614-MPAR-102 clinical trial to evaluate its MPAR overdose-protection technology
EQUITY | Jun 26, 2026, 12:04 PM UTC
M
ENSC Enrolls Patient
Ensysce Biosciences enrolls first patient in final phase of PF614-MPAR-102 clinical study
EQUITY | Jun 26, 2026, 12:00 PM UTC